Prostaglandins and hypotensive lipids

-Adithya Phadnis
PROSTAGLANDINS AND
HYPOTENSIVE LIPIDS
What are prostaglandins?
 Prostaglandins, thromboxane and leukotriens are
eicosanoids which are metabolic products of 20-
carbon arachidonic acid.
 After they are synthesized they are transported
out of cells by transporters and are inactivated by
lungs and liver.
What are the prostanoid
receptors?
 There are 4 types EP,FP,IP and TP.
 FP receptor exists in two forms i) full length
receptor ii) splice variant.
How are prostaglandins made
bioavailable to FP receptor?
 Addition of a phenyl ring to the omega chain
improve d the selectivity to the FP receptor
agonist.
 To improve solubility the C-1 carboxyl group was
modified with an ethyl amide in case of
bimatoprost or an isopropyl ester for
latanoprost,travoprost.
 This modification at C-1 carboxy group creates a
lipophilic prodrug which is hydrolysed by the
cornea into the free acid drug form.
What is the mechanism of
action?
 FP receptors are G protein coupled receptors,
when stimulated it couples with phospholipase-C
which triggers the releae of the second
messenger induced phossphate production and
subsequently activates a molecular transduction
cascade that leads to IOP reduction.
What is the history of prostaglandins
in eye?
 In rabbits the topical application of 25 to 200
micro gram of prostaglandins caused initial
increase in IOP followed by reduction in IOP for
15-20 hours whereas 5 microgram produced
ocular hypotension without initial IOP rise.
How does PG descrease IOP?
 Increases the uveoscleral outflow(relaxation of
ciliary muscle)
 Remodelling of extracellular matrix of ciliary
muscle.
 Increase in matrix metalloproteinase that degrade
ecm substrates such as collagens,
fibronectin,laminin
Which are the ocular prostaglandin
analogs?
 Latanoprost-0.005%
 Travoprost-0.004%
 Bimatoprost-0.003%
What are the various uses of ocular
PG analogues
1) Chronic open angle glaucoma(superior to timolol
in IOP reduction in a 6 month study 31% vs 27%)
 Latanoprost (evening) vs (morning)-35% vs 31%
2) Safe in paediatric glaucoma
3) Effective in angle closure glaucoma
4) Effective in IOP reduction even when trabecular
meshwork was not seen upto 180 degrees from
25.0 +5.5 mm Hg to 17.5 +5 mm Hg.
5) Even effective in lowering IOP from 30.3 +4.5
mmHg to 21.5 + 5.9 mm Hg with 360 degrees of
PAS after 3 months of treatment.
6) In patients in whom peripheral iridotomy was
done and IOP reduction was not satifactory
latanoprost decreased IOP 34% vs timolol 23%.
Is bimatoprost superior to
latanoprost?
 In a community based Switch study in which
patients using latanoprost switched to
bimatoprost IOP reduction was 3.4 mm Hg after 2
months of treatment
How to store ocular PG analogs?
 Latanoprost- 25 degrees C upto 6 weeks
 Bimatoprost – 15 -25 degrees C
 Travoprost- 2 – 25 degrees C
What are the various drug
combinations?
1. With timolol- 13-37% additional reduction in IOP
2. With topical and oral carbonic anhydrase
3. With alpha 2 adrenergic agonist
(brimonidine+latanoprost vs timolol+ dorzolamide::
9.2 mmHg vs 6.7 mm Hg)
4. With pilocarpine- additional effect as it increases
trabecular outflow
When do you call latanoprost failure?
 When even after 6 to 8 months of Latanoprost
monotherapy there is <10% IOP reduction.
 Switch over to bimatoprost helps(24.1 mm Hg vs
18.2 mm Hg)
 Also note patients who have have high baseline
IOP Latanoprost monotherapy caused failure
What are the various side
effects?
1. Conjuctival hyperemia
 Latanoprost- 5-15%
 Bimatoprost-15-45%
 Travoprost-35-50%
 Unoprostone-10-25%
2. Decrease in conjunctival epithelial cell size by its
effect on fibroblast and matrix metalloproteinases.
3. Reactivation of herpes simplex keratitis.
4. Anterior uveitis and CME(absorptive transport
system of ciliary process appear to prevent
topically applied prostaglandins to cause retinal
toxicity- )
5. Increased pigmentation of periocular
skin(reversible and advise the patient to wipe off
excess drug)
6. Darkening of iris in 10%
7. hypertrichosis- beneficial cosmetically(stimulates
hair growth phase in dermal papilla)
8. Contact dermatitis, iri cyst
What is rhe reason for pigmentation?
 Prostaglandins increase the tyrosine kinase
activity in melanocytes thereby increases melanin
but not proliferation of melanocytes.
1 de 19

Recomendados

REVIEW OF ANTIGLAUCOMATOUS DRUGS por
 REVIEW OF ANTIGLAUCOMATOUS DRUGS REVIEW OF ANTIGLAUCOMATOUS DRUGS
REVIEW OF ANTIGLAUCOMATOUS DRUGSAlexis Galeno Matos
555 vistas4 diapositivas
Adrenergic drugs drugs for glaucoma por
Adrenergic drugs drugs for glaucomaAdrenergic drugs drugs for glaucoma
Adrenergic drugs drugs for glaucomaSubramani Parasuraman
3.7K vistas18 diapositivas
Glaucoma por
GlaucomaGlaucoma
GlaucomaSujata Jha
158 vistas26 diapositivas
Drugs for glaucoma por
Drugs for glaucomaDrugs for glaucoma
Drugs for glaucomaKoppala RVS Chaitanya
1.5K vistas25 diapositivas
Glaucoma management,dr.a.r.rajalakhmi,11.05.16 por
Glaucoma management,dr.a.r.rajalakhmi,11.05.16Glaucoma management,dr.a.r.rajalakhmi,11.05.16
Glaucoma management,dr.a.r.rajalakhmi,11.05.16ophthalmgmcri
8.6K vistas40 diapositivas
Newer drugs in Glaucoma Mangement por
Newer drugs in Glaucoma MangementNewer drugs in Glaucoma Mangement
Newer drugs in Glaucoma MangementShylesh Dabke
6.3K vistas33 diapositivas

Más contenido relacionado

La actualidad más candente

Anti glaucoma drugs por
Anti glaucoma drugsAnti glaucoma drugs
Anti glaucoma drugsankita mahapatra
17.5K vistas32 diapositivas
BETA -BLOCKERS AND GLAUCOMA por
BETA -BLOCKERS AND GLAUCOMABETA -BLOCKERS AND GLAUCOMA
BETA -BLOCKERS AND GLAUCOMAshrinathraman
4.8K vistas16 diapositivas
Medical treatment of primary open angle glaucoma por
Medical treatment of primary open angle glaucomaMedical treatment of primary open angle glaucoma
Medical treatment of primary open angle glaucomaAdithya Phadnis
2.3K vistas53 diapositivas
Objective 11 por
Objective 11Objective 11
Objective 11SarahSaeedAhmed
418 vistas3 diapositivas
Anti Glaucoma Drugs por
Anti Glaucoma DrugsAnti Glaucoma Drugs
Anti Glaucoma DrugsNishan Lamichhane
82 vistas29 diapositivas
Medical Treatment for Glaucoma por
Medical Treatment for GlaucomaMedical Treatment for Glaucoma
Medical Treatment for GlaucomaMutahir Shah
15.5K vistas20 diapositivas

La actualidad más candente(20)

BETA -BLOCKERS AND GLAUCOMA por shrinathraman
BETA -BLOCKERS AND GLAUCOMABETA -BLOCKERS AND GLAUCOMA
BETA -BLOCKERS AND GLAUCOMA
shrinathraman4.8K vistas
Medical treatment of primary open angle glaucoma por Adithya Phadnis
Medical treatment of primary open angle glaucomaMedical treatment of primary open angle glaucoma
Medical treatment of primary open angle glaucoma
Adithya Phadnis2.3K vistas
Medical Treatment for Glaucoma por Mutahir Shah
Medical Treatment for GlaucomaMedical Treatment for Glaucoma
Medical Treatment for Glaucoma
Mutahir Shah15.5K vistas
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur... por Bikash Sapkota
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...
Anti-glaucoma Drugs /Anti glaucoma eye drops/ Glaucoma Medications (healthkur...
Bikash Sapkota93.6K vistas
Drugs used in glaucoma and myasthenia gravis por Satyajit Ghosh
Drugs used in glaucoma and myasthenia gravisDrugs used in glaucoma and myasthenia gravis
Drugs used in glaucoma and myasthenia gravis
Satyajit Ghosh83 vistas
3 4 cholinergic pharmacology younus h johan 2016 por younus johan
3 4 cholinergic pharmacology younus h johan 20163 4 cholinergic pharmacology younus h johan 2016
3 4 cholinergic pharmacology younus h johan 2016
younus johan411 vistas
Newer treatment modalities of glaucoma por Atif Rahman
Newer treatment modalities of glaucomaNewer treatment modalities of glaucoma
Newer treatment modalities of glaucoma
Atif Rahman923 vistas
Glaucoma Treatment & Mydriatics por M S
Glaucoma Treatment & MydriaticsGlaucoma Treatment & Mydriatics
Glaucoma Treatment & Mydriatics
M S1.6K vistas
Pharmacotherapy of glaucoma por Dr.Arka Mondal
Pharmacotherapy of glaucomaPharmacotherapy of glaucoma
Pharmacotherapy of glaucoma
Dr.Arka Mondal549 vistas
Glaucoma Treatment por homebwoi
Glaucoma TreatmentGlaucoma Treatment
Glaucoma Treatment
homebwoi2.9K vistas

Similar a Prostaglandins and hypotensive lipids

Medical surgical management of copd (GOLD 2016-2017) por
Medical surgical management of copd (GOLD 2016-2017)Medical surgical management of copd (GOLD 2016-2017)
Medical surgical management of copd (GOLD 2016-2017)dr yogendra rathore
3.6K vistas82 diapositivas
Metformin Synthesis por
Metformin SynthesisMetformin Synthesis
Metformin SynthesisCarolina Cardona
5 vistas40 diapositivas
Development and Validation of an RP HPLC Method for Analysis of Sitagliptin por
Development and Validation of an RP HPLC Method for Analysis of SitagliptinDevelopment and Validation of an RP HPLC Method for Analysis of Sitagliptin
Development and Validation of an RP HPLC Method for Analysis of Sitagliptinijtsrd
272 vistas5 diapositivas
Design and Synthesis of some Pyrimidine as DPP-IV Inhibitors por
Design and Synthesis of some Pyrimidine as DPP-IV InhibitorsDesign and Synthesis of some Pyrimidine as DPP-IV Inhibitors
Design and Synthesis of some Pyrimidine as DPP-IV Inhibitorsmohd imran Ahmad
354 vistas48 diapositivas
Drug Interactions of ADP receptor Blockers (Antiplatelets) por
 Drug Interactions of ADP receptor Blockers (Antiplatelets) Drug Interactions of ADP receptor Blockers (Antiplatelets)
Drug Interactions of ADP receptor Blockers (Antiplatelets)Naina Mohamed, PhD
2.1K vistas23 diapositivas
Development and Validation of Analytical Methods for Simultaneous Spectrophot... por
Development and Validation of Analytical Methods for Simultaneous Spectrophot...Development and Validation of Analytical Methods for Simultaneous Spectrophot...
Development and Validation of Analytical Methods for Simultaneous Spectrophot...ijtsrd
69 vistas4 diapositivas

Similar a Prostaglandins and hypotensive lipids(20)

Medical surgical management of copd (GOLD 2016-2017) por dr yogendra rathore
Medical surgical management of copd (GOLD 2016-2017)Medical surgical management of copd (GOLD 2016-2017)
Medical surgical management of copd (GOLD 2016-2017)
dr yogendra rathore3.6K vistas
Development and Validation of an RP HPLC Method for Analysis of Sitagliptin por ijtsrd
Development and Validation of an RP HPLC Method for Analysis of SitagliptinDevelopment and Validation of an RP HPLC Method for Analysis of Sitagliptin
Development and Validation of an RP HPLC Method for Analysis of Sitagliptin
ijtsrd272 vistas
Design and Synthesis of some Pyrimidine as DPP-IV Inhibitors por mohd imran Ahmad
Design and Synthesis of some Pyrimidine as DPP-IV InhibitorsDesign and Synthesis of some Pyrimidine as DPP-IV Inhibitors
Design and Synthesis of some Pyrimidine as DPP-IV Inhibitors
mohd imran Ahmad354 vistas
Drug Interactions of ADP receptor Blockers (Antiplatelets) por Naina Mohamed, PhD
 Drug Interactions of ADP receptor Blockers (Antiplatelets) Drug Interactions of ADP receptor Blockers (Antiplatelets)
Drug Interactions of ADP receptor Blockers (Antiplatelets)
Naina Mohamed, PhD2.1K vistas
Development and Validation of Analytical Methods for Simultaneous Spectrophot... por ijtsrd
Development and Validation of Analytical Methods for Simultaneous Spectrophot...Development and Validation of Analytical Methods for Simultaneous Spectrophot...
Development and Validation of Analytical Methods for Simultaneous Spectrophot...
ijtsrd69 vistas
Combination Therapy for Glaucoma Management (1).pptx por JyotiNikale
Combination Therapy for Glaucoma Management (1).pptxCombination Therapy for Glaucoma Management (1).pptx
Combination Therapy for Glaucoma Management (1).pptx
JyotiNikale24 vistas
Liraglutide in Diabetes por SAKEEL AHMED
Liraglutide in Diabetes Liraglutide in Diabetes
Liraglutide in Diabetes
SAKEEL AHMED359 vistas
Membrane technology in prophylactic biologicals in milk por Parth Hirpara
Membrane technology in prophylactic biologicals in milkMembrane technology in prophylactic biologicals in milk
Membrane technology in prophylactic biologicals in milk
Parth Hirpara238 vistas
Pharmacotherapy of Bronchial Asthma por Dr.Ravi K Sori
Pharmacotherapy of Bronchial AsthmaPharmacotherapy of Bronchial Asthma
Pharmacotherapy of Bronchial Asthma
Dr.Ravi K Sori540 vistas
Pharmacotherapy of glaucoma por DrSnehaDange
Pharmacotherapy of  glaucoma Pharmacotherapy of  glaucoma
Pharmacotherapy of glaucoma
DrSnehaDange621 vistas
Latoprost Eye Drops (Generic Latanoprost Ophthalmic Solution) por The Swiss Pharmacy
Latoprost Eye Drops (Generic Latanoprost Ophthalmic Solution)Latoprost Eye Drops (Generic Latanoprost Ophthalmic Solution)
Latoprost Eye Drops (Generic Latanoprost Ophthalmic Solution)
The Swiss Pharmacy1.1K vistas
Lecture on Ocular Pharmacology & Therapeutics For 4th Year MBBS Undergraduate... por DrHussainAhmadKhaqan
Lecture on Ocular Pharmacology & Therapeutics For 4th Year MBBS Undergraduate...Lecture on Ocular Pharmacology & Therapeutics For 4th Year MBBS Undergraduate...
Lecture on Ocular Pharmacology & Therapeutics For 4th Year MBBS Undergraduate...
Newer drugs for the treatment of motor symptoms of Parkinson's Disease por Sudhir Kumar
Newer drugs for the treatment of motor symptoms of Parkinson's DiseaseNewer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's Disease
Sudhir Kumar534 vistas

Último

The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enha... por
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enha...The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enha...
The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enha...PVI, PeerView Institute for Medical Education
14 vistas44 diapositivas
Myocardial Infarction Nursing.pptx por
Myocardial Infarction Nursing.pptxMyocardial Infarction Nursing.pptx
Myocardial Infarction Nursing.pptxAsraf Hussain
22 vistas73 diapositivas
MENSTRUAL CYCLE.pdf por
MENSTRUAL CYCLE.pdfMENSTRUAL CYCLE.pdf
MENSTRUAL CYCLE.pdfRutvikunvar Raualji (PT)
26 vistas24 diapositivas
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad por
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Swetha rani Savala
22 vistas16 diapositivas
OVARIES.pdf por
OVARIES.pdfOVARIES.pdf
OVARIES.pdfRutvikunvar Raualji (PT)
18 vistas15 diapositivas
Testicular tumors.pptx por
Testicular tumors.pptxTesticular tumors.pptx
Testicular tumors.pptxUtkarsh Singhal
32 vistas64 diapositivas

Último(20)

Myocardial Infarction Nursing.pptx por Asraf Hussain
Myocardial Infarction Nursing.pptxMyocardial Infarction Nursing.pptx
Myocardial Infarction Nursing.pptx
Asraf Hussain22 vistas
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad por Swetha rani Savala
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Swetha rani Savala22 vistas
Biomedicine & Pharmacotherapy por Trustlife
Biomedicine & PharmacotherapyBiomedicine & Pharmacotherapy
Biomedicine & Pharmacotherapy
Trustlife220 vistas
eTEP -RS Dr.TVR.pptx por Varunraju9
eTEP -RS Dr.TVR.pptxeTEP -RS Dr.TVR.pptx
eTEP -RS Dr.TVR.pptx
Varunraju9148 vistas
Trustlife Türkiye - Güncel Platform Yapısı por Trustlife
Trustlife Türkiye - Güncel Platform YapısıTrustlife Türkiye - Güncel Platform Yapısı
Trustlife Türkiye - Güncel Platform Yapısı
Trustlife43 vistas
communication and nurse patient relationship by Tamanya Samui.pdf por TamanyaSamui1
communication and nurse patient relationship by Tamanya Samui.pdfcommunication and nurse patient relationship by Tamanya Samui.pdf
communication and nurse patient relationship by Tamanya Samui.pdf
TamanyaSamui133 vistas
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx por ABG
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
ABG120 vistas
Correct handling of laboratory Rats ppt.pptx por TusharChaudhary99
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptx
TusharChaudhary9932 vistas
Pulmonary Embolism for Nurses.pptx por Asraf Hussain
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptx
Asraf Hussain36 vistas

Prostaglandins and hypotensive lipids

  • 2. What are prostaglandins?  Prostaglandins, thromboxane and leukotriens are eicosanoids which are metabolic products of 20- carbon arachidonic acid.  After they are synthesized they are transported out of cells by transporters and are inactivated by lungs and liver.
  • 3. What are the prostanoid receptors?  There are 4 types EP,FP,IP and TP.  FP receptor exists in two forms i) full length receptor ii) splice variant.
  • 4. How are prostaglandins made bioavailable to FP receptor?  Addition of a phenyl ring to the omega chain improve d the selectivity to the FP receptor agonist.  To improve solubility the C-1 carboxyl group was modified with an ethyl amide in case of bimatoprost or an isopropyl ester for latanoprost,travoprost.  This modification at C-1 carboxy group creates a lipophilic prodrug which is hydrolysed by the cornea into the free acid drug form.
  • 5. What is the mechanism of action?  FP receptors are G protein coupled receptors, when stimulated it couples with phospholipase-C which triggers the releae of the second messenger induced phossphate production and subsequently activates a molecular transduction cascade that leads to IOP reduction.
  • 6. What is the history of prostaglandins in eye?  In rabbits the topical application of 25 to 200 micro gram of prostaglandins caused initial increase in IOP followed by reduction in IOP for 15-20 hours whereas 5 microgram produced ocular hypotension without initial IOP rise.
  • 7. How does PG descrease IOP?  Increases the uveoscleral outflow(relaxation of ciliary muscle)  Remodelling of extracellular matrix of ciliary muscle.  Increase in matrix metalloproteinase that degrade ecm substrates such as collagens, fibronectin,laminin
  • 8. Which are the ocular prostaglandin analogs?  Latanoprost-0.005%  Travoprost-0.004%  Bimatoprost-0.003%
  • 9. What are the various uses of ocular PG analogues 1) Chronic open angle glaucoma(superior to timolol in IOP reduction in a 6 month study 31% vs 27%)  Latanoprost (evening) vs (morning)-35% vs 31% 2) Safe in paediatric glaucoma
  • 10. 3) Effective in angle closure glaucoma 4) Effective in IOP reduction even when trabecular meshwork was not seen upto 180 degrees from 25.0 +5.5 mm Hg to 17.5 +5 mm Hg. 5) Even effective in lowering IOP from 30.3 +4.5 mmHg to 21.5 + 5.9 mm Hg with 360 degrees of PAS after 3 months of treatment.
  • 11. 6) In patients in whom peripheral iridotomy was done and IOP reduction was not satifactory latanoprost decreased IOP 34% vs timolol 23%.
  • 12. Is bimatoprost superior to latanoprost?  In a community based Switch study in which patients using latanoprost switched to bimatoprost IOP reduction was 3.4 mm Hg after 2 months of treatment
  • 13. How to store ocular PG analogs?  Latanoprost- 25 degrees C upto 6 weeks  Bimatoprost – 15 -25 degrees C  Travoprost- 2 – 25 degrees C
  • 14. What are the various drug combinations? 1. With timolol- 13-37% additional reduction in IOP 2. With topical and oral carbonic anhydrase 3. With alpha 2 adrenergic agonist (brimonidine+latanoprost vs timolol+ dorzolamide:: 9.2 mmHg vs 6.7 mm Hg) 4. With pilocarpine- additional effect as it increases trabecular outflow
  • 15. When do you call latanoprost failure?  When even after 6 to 8 months of Latanoprost monotherapy there is <10% IOP reduction.  Switch over to bimatoprost helps(24.1 mm Hg vs 18.2 mm Hg)  Also note patients who have have high baseline IOP Latanoprost monotherapy caused failure
  • 16. What are the various side effects? 1. Conjuctival hyperemia  Latanoprost- 5-15%  Bimatoprost-15-45%  Travoprost-35-50%  Unoprostone-10-25%
  • 17. 2. Decrease in conjunctival epithelial cell size by its effect on fibroblast and matrix metalloproteinases. 3. Reactivation of herpes simplex keratitis. 4. Anterior uveitis and CME(absorptive transport system of ciliary process appear to prevent topically applied prostaglandins to cause retinal toxicity- )
  • 18. 5. Increased pigmentation of periocular skin(reversible and advise the patient to wipe off excess drug) 6. Darkening of iris in 10% 7. hypertrichosis- beneficial cosmetically(stimulates hair growth phase in dermal papilla) 8. Contact dermatitis, iri cyst
  • 19. What is rhe reason for pigmentation?  Prostaglandins increase the tyrosine kinase activity in melanocytes thereby increases melanin but not proliferation of melanocytes.